Drug intelligence / Profile preview

KRASG12D inhibitor

Development stage: Preclinical
Lead developer: Eilean Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

The KRASG12D inhibitor is an orally bioavailable small molecule therapeutic being developed by Eilean Therapeutics for the treatment of solid tumors. It specifically targets the G12D mutation of the KRAS protein, a common oncogenic driver in various cancers, including pancreatic, colorectal, and lung adenocarcinomas. By inhibiting the KRAS G12D mutant, the drug aims to disrupt downstream signaling pathways that promote tumor cell proliferation and survival. The program is currently in the early stages of development, focusing on achieving potent and selective inhibition with favorable oral pharmacokinetics.

Other names: KRAS G12D inhibitor

Targets

KRASG12D (Kirsten rat sarcoma viral oncogene homolog (KRAS) G12D mutant)

Beyond the preview

Go deeper on KRASG12D inhibitor.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KRASG12D inhibitor.

Explore the full profile